radium Ra 223 dichloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4800 444811-40-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Ra 223 dichloride
  • radium chloride RA-223
  • radium Ra 223 dichloride
  • xofigo
  • alpharadin
  • BAY 88-8223
  • radium (223Ra) dichloride
  • radium RA-223 dichloride
  • Radium-223 dichloride
  • Molecular weight: 293.92
  • Formula: Cl2Ra
  • CLOGP: -1.32
  • LIPINSKI: None
  • HAC: 0
  • HDO: 0
  • TPSA:
  • ALOGS: -0.60
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 15, 2013 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 1152.04 31.46 311 6612 14369 34935639
Metastases to bone 630.27 31.46 186 6737 11784 34938224
Metastases to liver 392.88 31.46 134 6789 13529 34936479
Bone pain 246.97 31.46 107 6816 20579 34929429
Prostate cancer metastatic 231.57 31.46 73 6850 5730 34944278
General physical health deterioration 197.63 31.46 179 6744 128090 34821918
Anaemia 192.73 31.46 233 6690 233102 34716906
Metastases to lymph nodes 190.80 31.46 60 6863 4668 34945340
Spinal cord compression 166.88 31.46 52 6871 3923 34946085
Prostate cancer 162.91 31.46 100 6823 39549 34910459
Osteonecrosis of jaw 151.76 31.46 73 6850 17816 34932192
Haemoglobin decreased 146.78 31.46 148 6775 120624 34829384
Prostate cancer stage IV 128.02 31.46 38 6885 2430 34947578
Metastasis 124.23 31.46 42 6881 4102 34945906
Metastases to spine 113.48 31.46 35 6888 2549 34947459
Disease progression 108.98 31.46 120 6803 107957 34842051
Platelet count decreased 103.93 31.46 123 6800 119594 34830414
Laboratory test abnormal 103.48 31.46 59 6864 20332 34929676
Pathological fracture 102.74 31.46 37 6886 4354 34945654
Metastases to lung 97.51 31.46 44 6879 9276 34940732
Death 96.79 31.46 230 6693 397819 34552189
Bone marrow failure 81.61 31.46 58 6865 29195 34920813
Full blood count abnormal 81.48 31.46 49 6874 18619 34931389
Blood test abnormal 76.39 31.46 34 6889 6937 34943071
Pancytopenia 74.70 31.46 93 6830 95064 34854944
Pain 72.29 31.46 138 6785 204537 34745471
Thrombocytopenia 68.76 31.46 116 6807 156131 34793877
Hospitalisation 65.73 31.46 68 6855 56834 34893174
Metastases to soft tissue 62.46 31.46 15 6908 421 34949587
Metastases to central nervous system 62.09 31.46 31 6892 8174 34941834
Malignant neoplasm progression 59.60 31.46 80 6843 87966 34862042
Hormone-refractory prostate cancer 59.25 31.46 16 6907 724 34949284
Metastases to bone marrow 54.42 31.46 14 6909 524 34949484
Blood alkaline phosphatase increased 52.67 31.46 46 6877 31129 34918879
Prostate cancer recurrent 49.93 31.46 15 6908 998 34949010
Malaise 48.75 31.46 111 6812 185714 34764294
Decreased appetite 47.69 31.46 103 6820 166289 34783719
Cancer pain 46.03 31.46 18 6905 2654 34947354
Traumatic fracture 40.26 31.46 10 6913 324 34949684
Femur fracture 39.82 31.46 23 6900 8101 34941907
Blood alkaline phosphatase decreased 39.60 31.46 12 6911 822 34949186
Bone marrow infiltration 39.27 31.46 9 6914 205 34949803
Asthenia 33.01 31.46 115 6808 245136 34704872
Spinal compression fracture 31.86 31.46 19 6904 7097 34942911

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 954.70 34.92 200 4689 10186 79729313
Metastases to bone 382.69 34.92 114 4775 24313 79715186
Metastases to liver 244.29 34.92 84 4805 28230 79711269
Anaemia 218.72 34.92 195 4694 444820 79294679
Prostate cancer metastatic 195.15 34.92 46 4843 3961 79735538
Bone pain 157.49 34.92 74 4815 55668 79683831
Prostate cancer 138.53 34.92 58 4831 33210 79706289
Metastases to lymph nodes 130.52 34.92 41 4848 10356 79729143
Osteonecrosis of jaw 127.05 34.92 59 4830 43167 79696332
Platelet count decreased 123.17 34.92 99 4790 194565 79544934
Haemoglobin decreased 117.81 34.92 102 4787 222017 79517482
General physical health deterioration 112.10 34.92 109 4780 275129 79464370
Death 110.05 34.92 153 4736 566361 79173138
Laboratory test abnormal 100.56 34.92 44 4845 28004 79711495
Metastases to spine 93.56 34.92 26 4863 4298 79735201
Hospitalisation 88.86 34.92 61 4828 94175 79645324
Pathological fracture 85.88 34.92 30 4859 10507 79728992
Spinal cord compression 83.59 34.92 26 4863 6351 79733148
Prostate cancer stage IV 83.25 34.92 21 4868 2393 79737106
Thrombocytopenia 77.38 34.92 88 4801 265171 79474328
Metastases to lung 76.67 34.92 32 4857 18131 79721368
Pancytopenia 75.62 34.92 70 4819 165675 79573824
Metastases to soft tissue 75.00 34.92 15 4874 594 79738905
Blood test abnormal 67.43 34.92 29 4860 17681 79721818
Metastasis 65.46 34.92 22 4867 6858 79732641
Bone marrow failure 65.15 34.92 40 4849 51067 79688432
Full blood count abnormal 60.22 34.92 35 4854 40439 79699060
Decreased appetite 58.13 34.92 87 4802 342331 79397168
Prostate cancer recurrent 53.80 34.92 12 4877 806 79738693
Hormone-refractory prostate cancer 48.75 34.92 10 4879 450 79739049
Cancer pain 46.86 34.92 16 4873 5229 79734270
Metastases to central nervous system 43.90 34.92 21 4868 16354 79723145
Blood alkaline phosphatase increased 43.59 34.92 34 4855 63630 79675869

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V10XX03 VARIOUS
THERAPEUTIC RADIOPHARMACEUTICALS
OTHER THERAPEUTIC RADIOPHARMACEUTICALS
Various therapeutic radiopharmaceuticals
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35232 radiopharmaceuticals
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Malignant tumor of prostate indication 399068003 DOID:10283




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4037730 VANDF
CHEBI:74895 CHEBI
CHEMBL2107816 ChEMBL_ID
C581106 MESH_SUPPLEMENTAL_RECORD_UI
DB08913 DRUGBANK_ID
RJ00KV3VTG UNII
1424174 RXNORM
203076 MMSL
29462 MMSL
d08101 MMSL
015032 NDDF
C3541342 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xofigo HUMAN PRESCRIPTION DRUG LABEL 1 50419-208 INJECTION 30 uCi INTRAVENOUS NDA 27 sections
Xofigo HUMAN PRESCRIPTION DRUG LABEL 1 50419-208 INJECTION 30 uCi INTRAVENOUS NDA 27 sections